DK1086137T3 - Sammensætning og fremgangsmåde til at modulere dendritisk T-celle cellevekselvirkning - Google Patents
Sammensætning og fremgangsmåde til at modulere dendritisk T-celle cellevekselvirkningInfo
- Publication number
- DK1086137T3 DK1086137T3 DK00921181T DK00921181T DK1086137T3 DK 1086137 T3 DK1086137 T3 DK 1086137T3 DK 00921181 T DK00921181 T DK 00921181T DK 00921181 T DK00921181 T DK 00921181T DK 1086137 T3 DK1086137 T3 DK 1086137T3
- Authority
- DK
- Denmark
- Prior art keywords
- cells
- cell
- antibody
- sign
- clumping
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000008611 intercellular interaction Effects 0.000 title 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 7
- 210000004027 cell Anatomy 0.000 abstract 5
- 108090000342 C-Type Lectins Proteins 0.000 abstract 2
- 102000003930 C-Type Lectins Human genes 0.000 abstract 2
- 108010037897 DC-specific ICAM-3 grabbing nonintegrin Proteins 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 108010030351 DEC-205 receptor Proteins 0.000 abstract 1
- 102000006481 HIV Receptors Human genes 0.000 abstract 1
- 108010083930 HIV Receptors Proteins 0.000 abstract 1
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 abstract 1
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 230000006052 T cell proliferation Effects 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000003266 anti-allergic effect Effects 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000000842 anti-protozoal effect Effects 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003904 antiprotozoal agent Substances 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 229960001438 immunostimulant agent Drugs 0.000 abstract 1
- 239000003022 immunostimulating agent Substances 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
- 229960003444 immunosuppressant agent Drugs 0.000 abstract 1
- 230000001861 immunosuppressant effect Effects 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000002609 medium Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19990201204 EP1046651A1 (en) | 1999-04-19 | 1999-04-19 | Composition and method for modulating dendritic cell-T interaction |
| US17692400P | 2000-01-20 | 2000-01-20 | |
| PCT/NL2000/000253 WO2000063251A1 (en) | 1999-04-19 | 2000-04-19 | Composition and method for modulating dendritic cell-t cell interaction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1086137T3 true DK1086137T3 (da) | 2008-10-27 |
Family
ID=8240111
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK00921181T DK1086137T3 (da) | 1999-04-19 | 2000-04-19 | Sammensætning og fremgangsmåde til at modulere dendritisk T-celle cellevekselvirkning |
| DK04078220.3T DK1516881T3 (da) | 1999-04-19 | 2000-04-19 | Sammensætning og fremgangsmåde til modulering af dendritcelle-T-celle-interaktioner |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04078220.3T DK1516881T3 (da) | 1999-04-19 | 2000-04-19 | Sammensætning og fremgangsmåde til modulering af dendritcelle-T-celle-interaktioner |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US7148329B1 (da) |
| EP (3) | EP1046651A1 (da) |
| JP (2) | JP4989820B2 (da) |
| KR (3) | KR100952883B1 (da) |
| AT (2) | ATE398140T1 (da) |
| AU (1) | AU776317B2 (da) |
| CA (1) | CA2330231C (da) |
| DE (2) | DE60044621D1 (da) |
| DK (2) | DK1086137T3 (da) |
| ES (2) | ES2346877T3 (da) |
| HK (1) | HK1036285A1 (da) |
| NZ (1) | NZ508723A (da) |
| PT (2) | PT1086137E (da) |
| WO (1) | WO2000063251A1 (da) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1046651A1 (en) * | 1999-04-19 | 2000-10-25 | Koninklijke Universiteit Nijmegen | Composition and method for modulating dendritic cell-T interaction |
| US6515124B2 (en) * | 2000-02-09 | 2003-02-04 | Hoffman-La Roche Inc. | Dehydroamino acids |
| NZ534864A (en) * | 2000-05-08 | 2006-04-28 | Celldex Therapeutics Inc | Human monoclonal antibodies to dentritic cells |
| US7560534B2 (en) | 2000-05-08 | 2009-07-14 | Celldex Research Corporation | Molecular conjugates comprising human monoclonal antibodies to dendritic cells |
| CA2431990A1 (en) * | 2000-12-21 | 2002-06-27 | Stichting Katholieke Universiteit | Method for modulating the binding activity of a novel icam-3 binding receptor on sinusoidal endothelial cells in liver and lymph nodes |
| US20030013081A1 (en) | 2001-06-26 | 2003-01-16 | Olson William C. | Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection |
| US7022323B2 (en) | 2001-06-26 | 2006-04-04 | Progenics Pharmaceuticals, Inc. | Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection |
| ES2197826B1 (es) * | 2002-06-21 | 2005-04-01 | Consejo Superior De Investigaciones Cientificas | Compuesto terapeutico frente a la infeccion por leishmania y su uso. |
| WO2004026326A2 (en) * | 2002-09-20 | 2004-04-01 | Stichting Katholieke Universiteit | Antigen uptake receptor for candida albicans on dendritic cells |
| US7691591B2 (en) * | 2002-09-20 | 2010-04-06 | Stichting Katholieke Universiteit | Methods of identifying and isolating cells expressing DC-sign |
| US20040146948A1 (en) * | 2002-10-18 | 2004-07-29 | Centenary Institute Of Cancer Medicine And Cell Biology | Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments |
| US7427469B2 (en) | 2002-11-05 | 2008-09-23 | Institut Pasteur | Method of treating cytomegalovirus with DC-SIGN blockers |
| EP1562628B1 (en) * | 2002-11-05 | 2009-04-15 | Institut Pasteur | Dc-sign blockers and their use for preventing or treating viral infections. |
| EP1417965A1 (en) * | 2002-11-07 | 2004-05-12 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | C-type lectin binding molecules, identification and uses thereof |
| US9259459B2 (en) | 2003-01-31 | 2016-02-16 | Celldex Therapeutics Inc. | Antibody vaccine conjugates and uses therefor |
| EP1594533B1 (en) | 2003-01-31 | 2012-04-11 | Celldex Research Corporation | Antibody vaccine conjugates and uses therefor |
| JP5021309B2 (ja) * | 2003-10-16 | 2012-09-05 | ステファン ジョン ラルフ | 免疫調節性組成物およびその使用方法 |
| AU2011211337B2 (en) * | 2003-10-16 | 2014-10-02 | Cancure Limited | Immunomodulating compositions and uses therefor |
| US20080025913A1 (en) * | 2003-12-15 | 2008-01-31 | Bowdish Katherine S | Novel Anti-Dc-Sign Antibodies |
| EP1761248B1 (en) | 2004-03-19 | 2012-05-23 | Rodos BioTarget GmbH | Carbohydrate-derivatized liposomes for targeting cellular carbohydrate recognition domains of ctl/ctld lectins, and intracellular delivery of therapeutically active compounds |
| DK1765294T3 (da) * | 2004-05-12 | 2008-11-10 | Baxter Int | Nukleinsyremikrokugler samt deres fremstilling og afgivelse |
| US7884085B2 (en) * | 2004-05-12 | 2011-02-08 | Baxter International Inc. | Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes |
| EP2963118B1 (en) | 2005-06-01 | 2017-08-09 | California Institute of Technology | Method of targeted gene delivery using viral vectors |
| FR2895262B1 (fr) * | 2005-12-22 | 2009-07-17 | Lab Francais Du Fractionnement | Inhibition de la reponse immunitaire anti-fviii |
| AT503387B1 (de) * | 2006-03-27 | 2008-05-15 | Univ Wien | Pharmazeutische zusammensetzung zur vorbeugung von infektionen |
| WO2008011636A2 (en) * | 2006-07-21 | 2008-01-24 | California Institute Of Technology | Targeted gene delivery for dendritic cell vaccination |
| AU2008214077B2 (en) * | 2007-02-02 | 2012-12-13 | Baylor Research Institute | Multivariable antigens complexed with targeting humanized monoclonal antibody |
| TWI422594B (zh) | 2007-02-02 | 2014-01-11 | Baylor Res Inst | 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑 |
| NZ578696A (en) | 2007-02-02 | 2012-01-12 | Baylor Res Inst | Vaccines based on targeting antigen to dcir expressed an antigen-presenting cells |
| CN101970491A (zh) | 2007-08-30 | 2011-02-09 | 沃尔特及伊莱萨霍尔医学研究院 | 树突状细胞标记物及其用途 |
| KR20100087344A (ko) | 2007-10-29 | 2010-08-04 | 버지니아 테크 인터렉추얼 프라퍼티스, 인크. | 돼지 ＤＣ-ＳＩＧＮ, ＩＣＡＭ－３ 및 ＬＳＥＣｔｉｎ 및 이의 용도 |
| KR101811965B1 (ko) | 2007-11-07 | 2017-12-22 | 셀덱스 쎄라퓨틱스, 인크. | 인간 수지상 및 상피 세포 205(ｄｅｃ-205)에 결합하는 항체 |
| EP2770061B1 (en) | 2009-07-24 | 2018-10-24 | Immune Design Corp. | Non-integrating lentiviral vectors |
| US20120322085A1 (en) * | 2009-11-05 | 2012-12-20 | Osaka University | Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent |
| JP5690132B2 (ja) | 2010-06-17 | 2015-03-25 | 株式会社マーレ フィルターシステムズ | エンジンの換気システム |
| WO2012021512A2 (en) | 2010-08-10 | 2012-02-16 | Ecole Polytechnique Federale De Lausanne | Erythrocyte-binding therapeutics |
| US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| CN104583231B (zh) | 2012-03-30 | 2021-02-26 | 免疫设计公司 | 具有对表达dc-sign的细胞改善的转导效率的慢病毒载体粒子 |
| US9713635B2 (en) | 2012-03-30 | 2017-07-25 | Immune Design Corp. | Materials and methods for producing improved lentiviral vector particles |
| US8323662B1 (en) | 2012-03-30 | 2012-12-04 | Immune Design Corp. | Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein |
| DK2833914T3 (da) * | 2012-04-04 | 2019-03-11 | Vaxform Llc | Adjuvanssystem til oral vaccineadministration |
| WO2014046994A1 (en) * | 2012-09-18 | 2014-03-27 | University Of Washington Through Its Center For Commercialization | Compositions and methods for antigen targeting to cd180 |
| US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
| AU2015233084B2 (en) | 2014-02-21 | 2020-12-17 | Anokion Sa | Glycotargeting therapeutics |
| US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| EP3142691A4 (en) | 2014-05-16 | 2018-04-11 | Baylor Research Institute | Methods and compositions for treating autoimmune and inflammatory conditions |
| US10688178B2 (en) | 2015-06-30 | 2020-06-23 | Osaka University | AntiPlexin A1 agonist antibody |
| CN108210503A (zh) * | 2016-12-10 | 2018-06-29 | 高尚先 | 甘露糖在用于提高Treg细胞数量及其Foxp3因子表达水平的新用途 |
| EP3638296A1 (en) | 2017-06-16 | 2020-04-22 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US891992A (en) | 1907-06-27 | 1908-06-30 | Henry Hess | Method of forming conically-shaped ends upon rollers and other objects. |
| US5332567A (en) | 1989-08-24 | 1994-07-26 | Immunomedics | Detection and treatment of infections with immunoconjugates |
| US6248332B1 (en) * | 1990-10-05 | 2001-06-19 | Medarex, Inc. | Targeted immunostimulation with bispecific reagents |
| IE922308A1 (en) * | 1991-07-16 | 1993-01-27 | Bristol Myers Squibb Co | Inhibition of non-cd4 mediated hiv infection |
| AU7339294A (en) | 1993-07-22 | 1995-02-20 | Precision Valve Corporation | Multi-directional actuation overcap |
| US6084067A (en) | 1993-07-26 | 2000-07-04 | Dana-Farber Cancer Institute | CTLA4/CD28 ligands and uses therefor |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| CA2188812A1 (en) | 1994-05-26 | 1995-12-07 | Mark De Boer | New methods and compounds for the selective modulation of antigen-specific t-cell responsiveness |
| US5548275A (en) * | 1995-01-23 | 1996-08-20 | Shambayati; Ali | Alarm system for enclosing and protecting an area |
| US5643786A (en) | 1995-01-27 | 1997-07-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method for isolating dendritic cells |
| CA2211993A1 (en) * | 1995-01-31 | 1996-08-08 | The Rockefeller University | Identification of dec, (dentritic and epithelial cells, 205 kda), a receptor with c-type lectin domains, nucleic acids encoding dec, and uses thereof |
| US5871964A (en) * | 1996-07-15 | 1999-02-16 | Incyte Pharmaceuticals, Inc. | Human C-type lectin |
| US6046158A (en) * | 1996-12-20 | 2000-04-04 | Board Of Regents The University Of Texas Systems | Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof |
| US5935813A (en) * | 1997-03-20 | 1999-08-10 | Incyte Pharmaceuticals, Inc. | Human pancreatitis-associated protein |
| WO1998049306A1 (en) * | 1997-04-29 | 1998-11-05 | Incyte Pharmaceuticals, Inc. | Human c-type lectin |
| JP2002512524A (ja) | 1997-06-03 | 2002-04-23 | 財団法人相模中央化学研究所 | 膜貫通ドメインを有するヒト蛋白質及びそれをコードするｄｎａ |
| US6273443B1 (en) * | 1998-06-01 | 2001-08-14 | Sunrise Medical Hhg Inc. | Universal elevating leg rest assembly |
| EP1046651A1 (en) | 1999-04-19 | 2000-10-25 | Koninklijke Universiteit Nijmegen | Composition and method for modulating dendritic cell-T interaction |
| WO2001012811A1 (en) * | 1999-08-12 | 2001-02-22 | Urogenesys, Inc. | C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof |
| CA2431990A1 (en) | 2000-12-21 | 2002-06-27 | Stichting Katholieke Universiteit | Method for modulating the binding activity of a novel icam-3 binding receptor on sinusoidal endothelial cells in liver and lymph nodes |
| US20030232745A1 (en) * | 2001-06-26 | 2003-12-18 | Olson William C. | Uses of DC-sign and DC-Signr for inhibiting hepatitis C virus infection |
| US7022323B2 (en) | 2001-06-26 | 2006-04-04 | Progenics Pharmaceuticals, Inc. | Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection |
| US7265642B2 (en) * | 2003-12-09 | 2007-09-04 | Synergy Microwave Corporation | User-definable thermal drift voltage control oscillator |
-
1999
- 1999-04-19 EP EP19990201204 patent/EP1046651A1/en not_active Withdrawn
-
2000
- 2000-04-19 NZ NZ508723A patent/NZ508723A/en not_active IP Right Cessation
- 2000-04-19 DE DE60044621T patent/DE60044621D1/de not_active Expired - Lifetime
- 2000-04-19 EP EP00921181A patent/EP1086137B1/en not_active Expired - Lifetime
- 2000-04-19 PT PT00921181T patent/PT1086137E/pt unknown
- 2000-04-19 KR KR1020087023697A patent/KR100952883B1/ko not_active IP Right Cessation
- 2000-04-19 DE DE60039151T patent/DE60039151D1/de not_active Expired - Lifetime
- 2000-04-19 WO PCT/NL2000/000253 patent/WO2000063251A1/en active Application Filing
- 2000-04-19 CA CA2330231A patent/CA2330231C/en not_active Expired - Fee Related
- 2000-04-19 ES ES04078220T patent/ES2346877T3/es not_active Expired - Lifetime
- 2000-04-19 PT PT04078220T patent/PT1516881E/pt unknown
- 2000-04-19 ES ES00921181T patent/ES2307502T3/es not_active Expired - Lifetime
- 2000-04-19 DK DK00921181T patent/DK1086137T3/da active
- 2000-04-19 KR KR1020007014459A patent/KR20010071530A/ko not_active Application Discontinuation
- 2000-04-19 KR KR1020077020353A patent/KR100923340B1/ko not_active IP Right Cessation
- 2000-04-19 AT AT00921181T patent/ATE398140T1/de active
- 2000-04-19 JP JP2000612337A patent/JP4989820B2/ja not_active Expired - Fee Related
- 2000-04-19 DK DK04078220.3T patent/DK1516881T3/da active
- 2000-04-19 AU AU41526/00A patent/AU776317B2/en not_active Ceased
- 2000-04-19 AT AT04078220T patent/ATE472558T1/de active
- 2000-04-19 EP EP04078220A patent/EP1516881B1/en not_active Expired - Lifetime
- 2000-04-19 US US09/719,961 patent/US7148329B1/en not_active Expired - Fee Related
-
2001
- 2001-09-28 HK HK01106858A patent/HK1036285A1/ unknown
-
2003
- 2003-07-23 US US10/625,204 patent/US7285642B2/en not_active Expired - Fee Related
- 2003-07-23 US US10/625,202 patent/US8105599B2/en not_active Expired - Fee Related
-
2007
- 2007-10-22 US US11/977,151 patent/US8058400B2/en not_active Expired - Fee Related
-
2010
- 2010-08-05 JP JP2010176824A patent/JP5363432B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1086137T3 (da) | Sammensætning og fremgangsmåde til at modulere dendritisk T-celle cellevekselvirkning | |
| AU2016263198B2 (en) | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies | |
| CN109476745B (zh) | 拮抗性抗肿瘤坏死因子受体超家族抗体 | |
| ES2657443T3 (es) | Anticuerpos anti-GITR y usos de los mismos | |
| WO2017197347A1 (en) | METHODS FOR SELECTIVE EXPANSION OF γδ T-CELL POPULATIONS AND COMPOSITIONS THEREOF | |
| KR20180099641A (ko) | 세포의 배양 방법 및 이를 위한 키트와 장치 | |
| MX2012012833A (es) | Cebado cruzado de celulas t cd8 positivas humanos moderada por inmunoreceptores de celulas dendriticas (dcir). | |
| JPH10179151A (ja) | 二特異的抗体を用いた幹細胞移植における汚染腫瘍細胞の除去 | |
| KR20090114466A (ko) | 덱틴-1을 통한 사람 항원제시세포 활성화의 치료학적 적용 | |
| CA2321161A1 (en) | Compositions containing an ox-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response | |
| IL148113A0 (en) | Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof | |
| JP2013517330A (ja) | 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片 | |
| KR20090127886A (ko) | 수지상 세포 렉틴 유사 산화된 ｌｄｌ 수용체-1(ｌｏｘ-1)을 통한 사람 항원제시세포의 활성화 | |
| DK0969873T3 (da) | Multiple carbonhydratholdige glycopeptid-antigener, vaccine indeholdende dem og anvendelse deraf | |
| JP2022512401A (ja) | ハーボキシジエンスプライシング調節薬抗体－薬物コンジュゲート及びその使用方法 | |
| CN115315446A (zh) | 抗糖-cd44抗体及其用途 | |
| JPWO2020132024A5 (da) | ||
| US20210108176A1 (en) | Transduction and expansion of cells | |
| AU2018370120A1 (en) | Methods for selective expansion of d3 yd T-cell populations and compositions thereof | |
| CN116368222A (zh) | 破坏cd28-唾液酸糖苷配体复合物以增强t细胞活化 | |
| Nohara et al. | Gangliosides involved in activation of rat T lineage cells | |
| Liu et al. | Tumor-antigen expression-dependent activation of the CD137 costimulatory pathway by bispecific DART® proteins | |
| Yefenof et al. | Potentiation of NK cytotoxicity by antibody-C3b/iC3b heteroconjugates. | |
| JPWO2020219843A5 (da) | ||
| CN118354789A (zh) | 抗糖-cMET抗体及其用途 |